Healthcare Industry News: neuromodulation
News Release - November 11, 2009
BIOTRONIK, Inc., Names Dan Schlewitz Executive VP of SalesSales Leader Brings Fast Track Experience to Rapidly Growing U.S. Cardiac Rhythm Management Company
LAKE OSWEGO, Ore.--(HSMN NewsFeed)--BIOTRONIK, Inc., announced today that they have named Dan Schlewitz as Executive Vice President of Sales for their U.S. operations. Schlewitz will be responsible for leading the sales organization in order to further accelerate the company’s already impressive growth trend relative to competitors in the CRM market space.
Schlewitz has been a highly successful executive sales leader in the CRM industry for more than 25 years. In prior positions, he was the Vice President of Sales for the U.S. Cardiac Rhythm Disease Management Division of Medtronic, Inc., from the beginning of 2001 through the end of 2006. In this role, he was responsible for a sales and service organization that increased annual revenues from $1.4 billion to $3.2 billion. After successfully leading the CRDM Division, Schlewitz took on the challenge of leading Medtronic’s neuromodulation sector field sales organization. Schlewitz’s career is characterized throughout by outstanding success in building highly organized and focused sales organizations that exceed their goals.
“Dan rose to the top of our candidate list quickly because of his tremendous success in this challenging medical sales sector,” said Jake Langer, President, BIOTRONIK, Inc. “We are very pleased to have someone with Dan’s background and capabilities to lead our sales initiatives as we rapidly move through a pivotal growth stage in the U.S. market.”
BIOTRONIK, Inc., is well positioned to take full advantage of current uncertainties in the U.S. market that are creating multiple opportunities. “We are prepared to take full advantage of all of these opportunities,” said Langer. “Our controlled growth strategies were planned with contingencies that could be used to successfully navigate challenging economic conditions affecting our industry.”
BIOTRONIK, Inc., is unique in its ability to grow in spite of the broader industry trends toward flat or declining business driven by concerns over product performance and increased pressures exerted by proposed healthcare reform. Mr. Langer emphasized that “private ownership allows our company to remain steadfastly focused on the core tenets of success in the CRM market.” Delivering dependable, reliable products of uncompromising quality to physicians and to their patients is BIOTRONIK’s singular goal. “Dan’s exemplary track record of mobilizing a sales channel to deliver products and the service they require will drive BIOTRONIK’s success in this critical next phase.”
As one of the world’s leading cardiovascular medical device companies, with several million implanted devices, BIOTRONIK is represented in over 100 countries with its global workforce of more than 5,000 employees. Known for having its finger on the pulse of the medical community, BIOTRONIK assesses the challenges physicians face, and provides the best solutions for all phases of patient care, ranging from diagnosis to treatment to patient management. Quality, innovation and reliability define BIOTRONIK and its growing success, and deliver confidence and peace of mind to physicians and their patients worldwide.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.